The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 72 results:
Author [ Title(Desc)] Type Year
Filters: Keyword is Colorectal Neoplasms  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2
Tsalis, K., Ioannidis O., Cheva A., Savvala N. Antigoni, Antoniou N., Parpoudi S., et al. (2018).  A 20-year single center experience in the surgical treatment of colorectal liver metastasis.. J BUON. 23(6), 1640-1647.
A
Sato, F., Shibata D., Harpaz N., Xu Y., Yin J., Mori Y., et al. (2002).  Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma.. Cancer Res. 62(23), 6820-2.
Kountouras, J., Kapetanakis N., Zavos C., Polyzos S. A., Kouklakis G., Venizelos I., et al. (2014).  Active Helicobacter pylori infection is associated with colorectal mucosa-adenomatous polyp--early and advanced adenocarcinoma sequence.. Scand J Gastroenterol. 49(3), 381-2.
Kountouras, J., Kapetanakis N., Polyzos S. A., Katsinelos P., Gavalas E., Tzivras D., et al. (2017).  Active Infection Is a Risk Factor for Colorectal Mucosa: Early and Advanced Colonic Neoplasm Sequence.. Gut Liver. 11(5), 733-734.
Demetriades, H., Kanellos I., Vasiliadis K., Angelopoulos S., Vergos O., Kanellos D., et al. (2004).  Age-associated prognosis following curative resection for colorectal cancer.. Tech Coloproctol. 8 Suppl 1, s144-6.
Lakis, S., Papamitsou T., Panagiotopoulou C., Kotakidou R., & Kotoula V. (2010).  AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas.. World J Gastroenterol. 16(20), 2476-83.
Pentheroudakis, G., Kotoula V., Koliou G-A., Karavasilis V., Samantas E., Aravantinos G., et al. (2018).  AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.. Clin Colorectal Cancer. 17(4), e631-e637.
Pentheroudakis, G., Mavroeidis L., Papadopoulou K., Koliou G-A., Bamia C., Chatzopoulos K., et al. (2019).  Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.. Clin Colorectal Cancer. 18(4), e370-e384.
Selaru, F. M., Xu Y., Yin J., Zou T., Liu T. C., Mori Y., et al. (2002).  Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions.. Gastroenterology. 122(3), 606-13.
Rallis, G., Koletsa T., Saridaki Z., Manousou K., Koliou G-A., Kostopoulos I., et al. (2019).  Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer.. Anticancer Res. 39(4), 2129-2138.
B
Pentheroudakis, G., Kotoula V., De Roock W., Kouvatseas G., Papakostas P., Makatsoris T., et al. (2013).  Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.. BMC Cancer. 13, 49.
Pramateftakis, M. G., Hatzigianni P., Kanellos D., Vrakas G., Kanellos I., Agelopoulos S., et al. (2010).  Brain metastases in colorectal cancer.. Tech Coloproctol. 14 Suppl 1, S67-8.
C
Vamvakas, L., Athanasiadis A., Karampeazis A., Kakolyris S., Polyzos A., Kouroussis C., et al. (2010).  Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).. Crit Rev Oncol Hematol. 76(1), 61-70.
Basdanis, G., Michalopoulos A., Papadopoulos V., Tzeveleki I., Efthimiadis C., Kosmidis C., et al. (2004).  Clinical short-term results of radiofrequency ablation in patients with liver metastases from colorectal cancer.. Tech Coloproctol. 8 Suppl 1, s187-9.
Basdanis, G., Papadopoulos V. N., Michalopoulos A., Fahantidis E., Apostolidis S., Berovalis P., et al. (2004).  Colorectal cancer in patients over 70 years of age: determinants of outcome.. Tech Coloproctol. 8 Suppl 1, s112-5.
Evrard, S., Poston G., Kissmeyer-Nielsen P., Diallo A., Desolneux G., Brouste V., et al. (2014).  Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases.. PLoS One. 9(12), e114404.
Sgourakis, G., Papapanagiotou A., Kontovounisios C., Karamouzis M. V., Dedemadi G., Goumas C., et al. (2014).  The combined use of serum neurotensin and IL-8 as screening markers for colorectal cancer.. Tumour Biol. 35(6), 5993-6002.
Cohen, S. A., Yu M., Baker K., Redman M., Wu C., Heinzerling T. J., et al. (2017).  The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.. Clin Epigenetics. 9, 46.
Tsalis, K., Vasiliadis K., Christoforidis E., Vergos O., Angelopoulos S., Botsios D., et al. (2004).  Current treatment of colorectal liver metastases.. Tech Coloproctol. 8 Suppl 1, s174-6.
D
Giouleme, O., Diamantidis M. D., & Katsaros M. G. (2011).  Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms.. World J Gastroenterol. 17(4), 444-8.
Mastrokostas, A., Gavana M., Gkrizioti M., Smyrnakis E., Cholongitas E., Benos A., et al. (2018).  Discrepancies and misconceptions of perceived colorectal cancer screening barriers between primary health professionals and unscreened population. A comparative study in Greece.. J BUON. 23(7), 67-76.
Pavlidis, T. E., Marakis G., Ballas K., Rafailidis S., Psarras K., Pissas D., et al. (2008).  Does emergency surgery affect resectability of colorectal cancer?. Acta Chir Belg. 108(2), 219-25.
E
Pavlidis, E. T., Ballas K. D., Symeonidis N. G., Psarras K., Koliakos G., Kouzi-Koliakos K., et al. (2010).  The effect of bevacizumab on colon anastomotic healing in rats.. Int J Colorectal Dis. 25(12), 1465-73.
De Roock, W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., et al. (2010).  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.. Lancet Oncol. 11(8), 753-62.
Razis, E., Pentheroudakis G., Rigakos G., Bobos M., Kouvatseas G., Tzaida O., et al. (2014).  EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.. J Cancer Res Clin Oncol. 140(5), 737-48.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.